MedTrace Logo

A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism

NCT06881992 · Status: RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2026-05-18

No results posted yet for this study

Summary

The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).

Conditions

  • Tumor Hyperinsulinism (Tumor HI)

Interventions

DRUG

Ersodetug

Ersodetug (9 mg/kg) + SOC

Sponsors & Collaborators

  • Rezolute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-16
Primary Completion
2027-09-30
Completion
2027-09-30
FDA Drug
Yes

Countries

  • United States
  • France
  • Netherlands
  • Switzerland
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06881992 on ClinicalTrials.gov